2018 was another good year for Medistim, with continued growth and profitability. We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 22% measured as the share of bypass procedures done with Medistim’s devices.
During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and the United States participate. The results from the REQUEST study show that 25% of the patient population had one or more surgical changes in the procedure based on ultrasound and bloodstream data. This is a high figure, indicating that using TTFM and high-resolution ultrasound imaging has great clinical benefit during the CABG procedure, even for highly experienced surgeons. We are now looking forward to 2019 when the complete analysis and publication of the study will be ready.
Read the full report below (available in English and Norwegian).